glp-1 agonists vs bariatric surgery weight loss comparison Metabolic and versus glucagon-like peptide-1 receptor agonist therapy: A of cardiovascular outcomes in patients with obesity Patients Who Undergo Bariatric Surgery
Description
2023 Aug 5;402(10400):472-483.
Food and Drug Administration approved the first GLP-1 medications in 2005
Background Type 2 diabetes (T2D) and its frequent comorbidity, obesity, have traditionally been treated as separate clinical battles
510% weight loss is considered clinically meaningful with pharmacotherapy
He has also received grants from Medical Research Council, European Union, JPND, Alzheimers Research, UK, Alzheimers Drug Discovery Foundation, Alzheimers Society, UK, Alzheimers Association, US, Medical P.E
In healthy humans, GIP-mediated elevation of circulating glucagon concentrations has also been observed
